(Q38172643)

English

An update on the clinical development of proprotein convertase subtilisin kexin 9 inhibitors, novel therapeutic agents for lowering low-density lipoprotein cholesterol

scientific article published on April 2014

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

30 August 2017

An update on the clinical development of proprotein convertase subtilisin kexin 9 inhibitors, novel therapeutic agents for lowering low-density lipoprotein cholesterol (English)

1 reference

Europe PubMed Central

PubMed publication ID

30 August 2017

LDL cholesterol

0 references

1 reference

based on heuristic

inferred from title

author name string

Hua Ling

1

1 reference

Europe PubMed Central

PubMed publication ID

30 August 2017

Tammy L Burns

2

1 reference

Europe PubMed Central

PubMed publication ID

30 August 2017

Daniel E Hilleman

3

1 reference

Europe PubMed Central

PubMed publication ID

30 August 2017

publication date

1 April 2014

1 reference

Europe PubMed Central

PubMed publication ID

30 August 2017

Cardiovascular Therapeutics

1 reference

Europe PubMed Central

PubMed publication ID

30 August 2017

32

1 reference

Europe PubMed Central

PubMed publication ID

30 August 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

30 August 2017

82-88

1 reference

Europe PubMed Central

PubMed publication ID

30 August 2017

Mutations in PCSK9 cause autosomal dominant hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1111%2F1755-5922.12056

21 January 2018

Adenoviral-mediated expression of Pcsk9 in mice results in a low-density lipoprotein receptor knockout phenotype

1 reference

https://api.crossref.org/works/10.1111%2F1755-5922.12056

21 January 2018

Post-transcriptional regulation of low density lipoprotein receptor protein by proprotein convertase subtilisin/kexin type 9a in mouse liver.

1 reference

https://api.crossref.org/works/10.1111%2F1755-5922.12056

21 January 2018

Molecular biology of PCSK9: its role in LDL metabolism

1 reference

https://api.crossref.org/works/10.1111%2F1755-5922.12056

21 January 2018

The PCSK9 decade

1 reference

https://api.crossref.org/works/10.1111%2F1755-5922.12056

21 January 2018

Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9.

1 reference

https://api.crossref.org/works/10.1111%2F1755-5922.12056

21 January 2018

Sequence variations in PCSK9, low LDL, and protection against coronary heart disease

1 reference

https://api.crossref.org/works/10.1111%2F1755-5922.12056

21 January 2018

PCSK9 Inhibitors: potential in cardiovascular therapeutics

1 reference

https://api.crossref.org/works/10.1111%2F1755-5922.12056

21 January 2018

Effect of a monoclonal antibody to PCSK9 on LDL cholesterol

1 reference

https://api.crossref.org/works/10.1111%2F1755-5922.12056

21 January 2018

Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy

1 reference

https://api.crossref.org/works/10.1111%2F1755-5922.12056

21 January 2018

Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial.

1 reference

https://api.crossref.org/works/10.1111%2F1755-5922.12056

21 January 2018

Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase

1 reference

https://api.crossref.org/works/10.1111%2F1755-5922.12056

21 January 2018

Guidelines for the diagnosis and management of heterozygous familial hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1111%2F1755-5922.12056

21 January 2018

Update and analysis of the University College London low density lipoprotein receptor familial hypercholesterolemia database

1 reference

https://api.crossref.org/works/10.1111%2F1755-5922.12056

21 January 2018

Evaluation of cholesterol lowering treatment of patients with familial hypercholesterolemia: a large cross-sectional study in The Netherlands.

1 reference

https://api.crossref.org/works/10.1111%2F1755-5922.12056

21 January 2018

Effect of lipid-lowering treatment on natural history of heterozygous familial hypercholesterolemia in past three decades

1 reference

https://api.crossref.org/works/10.1111%2F1755-5922.12056

21 January 2018

Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised con

1 reference

https://api.crossref.org/works/10.1111%2F1755-5922.12056

21 January 2018

Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C with PCSK9 In

1 reference

https://api.crossref.org/works/10.1111%2F1755-5922.12056

21 January 2018

PCSK9 impedes hepatitis C virus infection in vitro and modulates liver CD81 expression

1 reference

https://api.crossref.org/works/10.1111%2F1755-5922.12056

21 January 2018

Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients--the PRIMO study

1 reference

https://api.crossref.org/works/10.1111%2F1755-5922.12056

21 January 2018

Systematic review and metaanalysis of statins for heterozygous familial hypercholesterolemia in children: evaluation of cholesterol changes and side effects

1 reference

https://api.crossref.org/works/10.1111%2F1755-5922.12056

21 January 2018

The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia

1 reference

https://api.crossref.org/works/10.1111%2F1755-5922.12056

21 January 2018

Intensive versus moderate lipid lowering with statins after acute coronary syndromes

1 reference

https://api.crossref.org/works/10.1111%2F1755-5922.12056

21 January 2018

Intensive lipid lowering with atorvastatin in patients with stable coronary disease

1 reference

https://api.crossref.org/works/10.1111%2F1755-5922.12056

21 January 2018

Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins

1 reference

https://api.crossref.org/works/10.1111%2F1755-5922.12056

21 January 2018

Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis

1 reference

https://api.crossref.org/works/10.1111%2F1755-5922.12056

21 January 2018

Novel putative SREBP and LXR target genes identified by microarray analysis in liver of cholesterol-fed mice

1 reference

https://api.crossref.org/works/10.1111%2F1755-5922.12056

21 January 2018

Statins upregulate PCSK9, the gene encoding the proprotein convertase neural apoptosis-regulated convertase-1 implicated in familial hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1111%2F1755-5922.12056

21 January 2018

Rosuvastatin, proprotein convertase subtilisin/kexin type 9 concentrations, and LDL cholesterol response: the JUPITER trial

1 reference

https://api.crossref.org/works/10.1111%2F1755-5922.12056

21 January 2018

Atorvastatin increases human serum levels of proprotein convertase subtilisin/kexin type 9.

1 reference

https://api.crossref.org/works/10.1111%2F1755-5922.12056

21 January 2018

High-dose atorvastatin causes a rapid sustained increase in human serum PCSK9 and disrupts its correlation with LDL cholesterol

1 reference

https://api.crossref.org/works/10.1111%2F1755-5922.12056

21 January 2018

Plasma PCSK9 is increased by fenofibrate and atorvastatin in a non-additive fashion in diabetic patients

1 reference

https://api.crossref.org/works/10.1111%2F1755-5922.12056

21 January 2018

Identifiers

10.1111/1755-5922.12056

1 reference

Europe PubMed Central

PubMed publication ID

30 August 2017

release_epxxp3e2tfg2bhi54mwr43wxhe

1 reference

https://api.fatcat.wiki/v0/release/epxxp3e2tfg2bhi54mwr43wxhe

24 November 2022

based on heuristic

mapped directly with Wikidata item

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

30 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38172643&oldid=2106954968"